Protalix BioTherapeutics (PLX) Competitors $1.51 -0.04 (-2.58%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.52 +0.00 (+0.33%) As of 07/25/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. TRML, RZLT, KMDA, PRTC, CGEM, RGNX, ERAS, AQST, SNDL, and CMPXShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Tourmaline Bio (TRML), Rezolute (RZLT), Kamada (KMDA), PureTech Health (PRTC), Cullinan Therapeutics (CGEM), REGENXBIO (RGNX), Erasca (ERAS), Aquestive Therapeutics (AQST), SNDL (SNDL), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Tourmaline Bio Rezolute Kamada PureTech Health Cullinan Therapeutics REGENXBIO Erasca Aquestive Therapeutics SNDL Compass Therapeutics Tourmaline Bio (NASDAQ:TRML) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Do analysts prefer TRML or PLX? Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 149.54%. Protalix BioTherapeutics has a consensus target price of $15.00, indicating a potential upside of 893.38%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, TRML or PLX? Tourmaline Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500. Do insiders and institutionals believe in TRML or PLX? 91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 13.0% of Tourmaline Bio shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TRML or PLX more profitable? Tourmaline Bio has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Tourmaline Bio's return on equity of -26.75% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -26.75% -26.11% Protalix BioTherapeutics -21.03%-30.89%-11.74% Which has better valuation and earnings, TRML or PLX? Protalix BioTherapeutics has higher revenue and earnings than Tourmaline Bio. Tourmaline Bio is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$73.21M-$3.21-6.16Protalix BioTherapeutics$59.76M2.01$8.31M$0.0437.75 Does the media prefer TRML or PLX? In the previous week, Tourmaline Bio and Tourmaline Bio both had 3 articles in the media. Tourmaline Bio's average media sentiment score of 1.03 beat Protalix BioTherapeutics' score of 0.25 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTourmaline Bio beats Protalix BioTherapeutics on 8 of the 13 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$120.21M$273.45M$5.70B$21.11BDividend YieldN/AN/A4.69%3.60%P/E Ratio-11.62N/A28.1028.44Price / Sales2.01364.38428.3558.68Price / Cash17.8022.4436.2222.92Price / Book3.2112.418.664.69Net Income$8.31M-$106.40M$3.25B$995.51M7 Day Performance4.14%5.20%4.22%1.65%1 Month Performance4.14%24.18%10.51%4.54%1 Year Performance31.88%10.55%34.40%9.99% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.9317 of 5 stars$1.51-2.6%$15.00+893.4%+31.3%$120.21M$59.76M-11.62200TRMLTourmaline Bio1.9066 of 5 stars$18.23-1.4%$49.33+170.6%+15.5%$468.15MN/A-5.6844News CoveragePositive NewsRZLTRezolute2.5508 of 5 stars$5.38-0.2%$11.83+120.0%+34.6%$468.06MN/A-4.6840News CoverageAnalyst RevisionKMDAKamada4.3342 of 5 stars$7.80+4.7%$13.00+66.7%+30.0%$448.54M$167.24M26.90360News CoverageGap UpPRTCPureTech Health2.7886 of 5 stars$18.56+0.3%$45.00+142.4%-14.4%$445.93M$4.32M0.00100Positive NewsUpcoming EarningsCGEMCullinan Therapeutics2.0211 of 5 stars$7.52-0.1%$30.00+298.9%-58.9%$444.38MN/A0.0030Positive NewsRGNXREGENXBIO4.1763 of 5 stars$8.49+4.0%$31.63+272.5%-37.7%$425.86M$83.33M-2.73370News CoveragePositive NewsERASErasca2.8999 of 5 stars$1.50flat$4.57+204.8%-46.8%$424.94MN/A-2.42120AQSTAquestive Therapeutics1.6988 of 5 stars$4.23+0.7%$10.14+139.8%+20.3%$417.18M$57.56M0.00160SNDLSNDL1.7051 of 5 stars$1.58+2.6%$4.00+153.2%-28.9%$415.19M$671.81M-5.452,516News CoverageUpcoming EarningsCMPXCompass Therapeutics3.0262 of 5 stars$3.07+2.3%$12.67+312.6%+202.9%$414.85M$850K0.0020Positive News Related Companies and Tools Related Companies Tourmaline Bio Alternatives Rezolute Alternatives Kamada Alternatives PureTech Health Alternatives Cullinan Therapeutics Alternatives REGENXBIO Alternatives Erasca Alternatives Aquestive Therapeutics Alternatives SNDL Alternatives Compass Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLX Stock Alerts